二种不同剂量阿托伐汀对急性冠脉综合征患者炎症介质、纤维蛋白原和临床预后的影响

Effects of two Dosage of atorvastatin on the levels of inflammatory mediators,Fibrinogen and clinic prognosis patients with acute coronary syndrome

目的观察二种不同剂量(10 mg、40 mg)阿托伐他汀治疗急性冠脉综合征(ACS)前后外周血C反应蛋白(CRP)、纤维蛋白原(Fig)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDC-C)的变化、安全性和临床预后的影响。方法72例ACS患者随机分为大剂量阿托伐他汀(40 mg/d)治疗组(38例)和常规剂量阿托伐他汀(10 mg/d)治疗组(34例),观察2组治疗前及治疗后8周CRP和Fig、TC、LDL-C的水平变化及6个月内主要冠脉不良事件(MACE)。结果治疗后大剂量阿托伐他汀治疗组CRP、Fig、TC、LDL-C水平及MACE发生率明显降低,与常规剂量阿托伐他汀治疗组比较有显著意义(P<0.05)。结论大剂量阿托伐他汀治疗ACS的疗效优于常规剂量组,同时未增加药物的毒副作用。

Objective To investigate the effect and safety and clinic prognosis of two dosage of Atovastatin in treatment of acute coronary Syndrome（ACS） through the change of C-reactive protein（ CRP）, Fibrinogen （Fig） ,total cholestrol（TC） , LDL-cholestrol （LDL-C）of patients with ACS before and after treatment with two dosage of Atorvastatin. Methods A total of 72 patients with ACS mere randomly assigned into the large dosage of Atorvastatin （ 40 mg/d ） group （ n = 38 ） and the routine dosage of Atorvastatin （ 10 mg/d） before and after 8 weeks treatment and major adverse coronary events（MACE） in six months were observed. Results In the large dosage of Atorvas tatin group, the levels of CRP, Fig, TC, LDL-C and MACE decreased Significantly comparing with the routine dosage of Atorvastatin group （ P 〈 0.05 ）. Conclusion The large dosage of Atorvastatin is better than routine dosage of Atorvastatin on treatment for ACS and of good safety.